loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Zydus Lifesciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Zydus Lifesciences Ltd. 06 Nov 2025 13:19 PM
Result PDF

Q2FY26 Quarterly Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals company Zydus Lifesciences announced Q2FY26 results

  • Revenue from operations at Rs 61,232 million, up 17% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 4,820 million (7.9% of revenues).
  • EBITDA for the quarter was Rs 20,158 million, up 38% YoY. EBITDA margin for the quarter stood at 32.9%, which is an improvementof 500 bps on a YoY basis.
  • Net Profit for the quarter was Rs 12,586 million, up 38% YoY.
  • Capex (organic) for the quarter was Rs 4,911 million.

Sharvil Patel, Managing Director, Zydus Lifesciences, said: Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech. These results reflect our commitment to sustainable growth and global expansion, anchored in quality, compliance, and patient-centric innovation.

Result PDF

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q1FY26 results

  • Revenue from Operations was Rs 65,737 million, up 6% YoY.
  • Research & Development (R&D) investments for the quarter stood at Rs 4,856 million (7.4% of revenue).
  • EBITDA for the quarter was Rs 20,885 million, flat YoY. EBITDA margin for the quarter stood at 31.8%.
  • Net Profit for the quarter was Rs 14,668 million, up 3% YoY.
  • Capex (organic) for the quarter was Rs 4,020 million.

Sharvil Patel, Managing Director, Zydus Lifesciences, said, "Our Q1FY26 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth. As we pursue these opportunities, we continue to keep the highest standards of compliance at the core of all our operations, while building strong future growth pillars that will strengthen our position globally".

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from operations at Rs 65,279 million, up 18% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 4,799 million (7.4% of revenues).
  • EBITDA for the quarter was Rs 21,255 million, up 30% YoY. EBITDA margin for the quarter stood at 32.6%, which is an improvement of 310 bps on a YoY basis.
  • Net Profit, adjusted for exceptional items, was Rs 13,905 million, up 18% YoY.
  • Capex (organic) for the quarter was Rs 3,202 million.

FY25 Financial Highlights:

  • Revenue from operations at Rs 2,32,415 million, up 19% over last year. • Research & Development (R&D) investments for the year stood at Rs 18,555 million (8.0% of revenues).
  • EBITDA for the year was Rs 70,585 million, up 31% YoY. EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year.
  • Net Profit, adjusted for exceptional items, was Rs 47,451 million, up 23% YoY.
  • Capex (organic) for the full year was Rs 12,140 million.
  • Net Debt to Equity ratio as on 31st March, 2025 was -0.20x while Net Debt to EBITDA stood at -0.69x at the end of March, 2025. Net Cash (negative Net Debt) as on March 31st, 2025 was Rs 48,836 million.

Sharvil Patel, Managing Director - Zydus Lifesciences said, "We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth. We look forward to continued execution success and deepening strategic partnerships to drive long term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering.”

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q3FY25 results

  • Revenue from operations at Rs 52,691 million, up 17% over Q3FY24.
  • Research & Development (R&D) investments for Q3FY25 stood at Rs 5,031 million (9.5% of revenues).
  • EBITDA for Q3FY25 was Rs 13,876 million, up 26% YoY. EBITDA margin for Q3FY25 stood at 26.3%, which is an improvement of 180 bps on a YoY basis.
  • Net Profit for Q3FY25 was Rs 10,235 million, up 30% YoY.
  • Capex (organic) for Q3FY25 was Rs 2,907 million.

Sharvil Patel, Managing Director, Zydus Lifesciences, said: We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations.

Result PDF

Pharmaceuticals company Zydus Lifesciences announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Revenue from operations at Rs 52,370 million, up 20% over Q2FY24.
  • Research & Development (R&D) investments for the Q2FY25 stood at Rs 4,800 million (9.2% of revenues).
  • EBITDA for the quarter was Rs 14,614 million, up 28% YoY. EBITDA margin for the quarter stood at 27.9% which is an improvement of 170 bps on a YoY basis.
  • Net Profit for the Q2FY25 was Rs 9,112 million, up 14% YoY.
  • Capex (organic) for the quarter was Rs 3,017 million.

H1FY25 Financial Highlights:

  • Revenue from operations at Rs 114,445 million, up 20% over H1FY24.
  • Research & Development (R&D) investments stood at Rs 8,725 million (7.6% of revenues).
  • EBITDA was Rs 35,454 million, up 34% YoY. EBITDA margin stood at 31%, which is an improvement of 310 bps over H1FY24.
  • Net Profit was Rs 23,311 million, up 24% YoY.
  • Capex (organic) for the half year was Rs 6,031 million.
  • Net Debt to Equity ratio as on 30th September, 2024 was -0.12x while Net Debt to EBITDA stood at -0.41x at the end of H1FY25.
  • Net Cash (negative Net Debt) as on H1FY25 was Rs 25,906 million.

Sharvil Patel, Managing Director - Zydus Lifesciences, said: Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions, keeping patient centricity at the core.

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q1FY25 results:

  • Total revenues grew 21% YoY to Rs 62,075 million, led by growth across businesses.
  • India branded formulations business posted double-digit growth and outpaced the market growth both in the chronic and acute segments.
  • Consumer Wellness business delivered an industry leading double-digit growth aided by improved demand scenario and extended summer.
  • US formulations business registered a robust sequential and y-o-y growth driven by new launches and volume expansion in base portfolio.
  • On the international markets front, demand scenario remained strong across key markets and drove the growth.
  • EBITDA margin stood at 33.6%, up 430 bps YoY.
  • Capex (organic) for the quarter: Rs 3,014 million.
  • Net cash: Rs 18,922 million (at 30-Jun’24) vs 8,561 million (at 31-Mar’24)

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations was Rs 55,338 million, up 10% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 3,516 million (6.4% of revenues).
  • EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis.
  • Net Profit for the quarter was Rs 11,823 million, up 299% YoY.
  • Capex (organic) for the quarter was Rs 2,126 million

FY24 Financial Highlights:

  • Revenue from operations was Rs 1,95,474 million, up 13% over last year.
  • Research & Development (R&D) investments stood at Rs 13,096 million (6.7% of revenues).
  • EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year.
  • Net Profit was Rs 38,595 million, up 97% YoY.
  • Capex (organic) for the year was Rs 8,628 million.
  • Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. 

Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation"

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q3FY24 & 9MFY24 results:

Consolidated Q3FY24:
- Revenue from operations stood at Rs 45,052 million, marking a 6% increase from the previous year.
- EBITDA for the quarter was reported at Rs 11,024 million, up 15% YoY, with an EBITDA margin of 24.5%, an increase of 200 basis points (bps) YoY.
- Research & Development (R&D) investment was Rs 3,146 million, representing 7.0% of revenues.
- The Net Profit for the quarter noted a significant rise of 27% YoY reaching Rs 7,896 million.
- Organic capital expenditure (Capex) for the quarter amounted to Rs 2,137 million.

Consolidated 9MFY24:
- Revenue from operations reached Rs 140,136 million, up by 15% compared to the last year.
- EBITDA for 9MFY24 stood at Rs 37,538 million indicating a 44% YoY increase. EBITDA margin was 26.8%, improving by 550 bps over the previous year.
- Research & Development (R&D) investment over nine months was Rs 9,580 million, equivalent to 6.8% of revenues.
- Net Profit surged by 61% YoY to Rs 26,772 million.
- Organic Capex for the nine months was Rs 6,502 million.

Business Segment Performance – Q3FY24
- India Geography: Reported revenue of Rs 18,247 million with an 11% YoY growth.
- US Formulations: Registered revenue of Rs 18,427 million, experiencing a slight decline of 4% YoY.
- Emerging Markets & Europe Formulations: Noted revenue of Rs 4,937 million, a substantial growth of 31% YoY.
- API Business: Revenue was at Rs 1,431 million, down by 24% YoY.
- Alliances & Others: Reported a sharp revenue increase of 59% YoY, reaching Rs 395 million.

Share Buyback
- Zydus Lifesciences announced a share buyback worth Rs 6000 million, representing 0.59% of total outstanding equity shares for Rs 1,005 per share, which is a 25% premium over the closing price as of February 8, 2024.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said, "We are pleased with our Q3FY24 performance, particularly with a strong recovery in the domestic formulations business and a resilient US base business. Importantly, our journey of sustained profitability improvement continues and we hope to sustain the same. We are optimistic about our growth prospects driven by a differentiated portfolio in the US, and the continued performance of key brands, well supported by a robust execution engine. We remain on track to end the fiscal year 2024 with a healthy double-digit revenue growth and expect to improve EBITDA margins to 27% plus levels."

 

 

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenue from operations at Rs 43,688 million, up 9% over last year.
    • Research & Development (R&D) investments for Q2FY24 stood at Rs 3,225 million (7.4% of revenues).
    • EBITDA for Q2FY24 was Rs 11,461 million, up 41% YoY. EBITDA margin for Q2FY24 stood at 26.2%, an improvement of 580 bps on a YoY basis.
    • Net Profit for Q2FY24 was Rs 8,007 million, up 53% YoY.
    • Capex (organic) for Q2FY24 was Rs 2,162 million.
  • H1FY24:
    • Revenue from operations at Rs 95,084 million, up 19% over last year.
    • Research & Development (R&D) investments stood at Rs 6,464 million (6.8% of revenues).
    • EBITDA was Rs 26,514 million, up 61% YoY. EBITDA margin stood at 27.9%, an improvement of 720 bps over the previous year.
    • Net Profit was Rs 18,876 million, up 81% YoY.
    • Capex (organic) for H1FY24 was Rs 4,365 million.

"Our Q2 FY24 result represents stable growth in our key businesses, as well as strong profitability. We are on track to meet our growth objectives for the year. Going ahead, differentiated launches in the US, in addition to a rebound in India business growth which was constrained by delayed seasonality, will be critical drivers. We anticipate sustained momentum in profitability and aim for EBITDA margins of more than 24% in the current fiscal year.", said, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences.

 

Result PDF

Pharmaceuticals company Zydus Lifesciences announced Q1FY24 results:

  • Revenue from operations at Rs 51,396 million, up 30% over last year.
  • Research & Development (R&D) investments for Q1FY24 stood at Rs 3,239 million (6.3% of revenues).
  • EBITDA for Q1FY24 was Rs 15,053 million, up 81% YoY.
  • EBITDA margin for Q1FY24 stood at 29.3% which is an improvement of 830 bps on a YoY basis.
  • Net Profit for Q1FY24 was Rs 10,869 million, up 110% YoY.
  • Capex (organic) for Q1FY24 was Rs 2,203 million.

Dr. Sharvil Patel Managing Director, Zydus Lifesciences, said, "We are delighted to deliver strong performance during the quarter with broad based operational growth in our key businesses and a favourable product mix enhancing our profitability. Strong execution and volume offtake drove revenue ramp-up in the US, while the India branded formulations business. adjusting for NLEM impact delivered solid 12% growth. We remain reassured of achieving profitable growth aspirations for the fiscal year and thereby enhancing stakeholder value. Our persistent commitment to maintaining high-quality standards and pursuing innovation will boost our sustainable growth prospects."

 

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status